Business
Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report
STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":" STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that an exclusive interview with CEO Snehal Patel will air on the upcoming The RedChip Money Report television program on Bloomberg International channel, which airs in approximately 100 million homes on Sundays at 6:00 pm local time in Europe.\n\nIn the interview, Mr. Patel discusses the Company’s development of GP2, including the positive Phase IIb clinical trial results where 0% breast cancer recurrences were observed over 5 years of follow-up, an overview of the planned Phase III trial, and upcoming milestones.\n\nTo watch the interview, click here.\n\nAbout The RedChip Money Report\n\nThe RedChip Money Report delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, and financial book reviews, as well as featured interviews with executives of public companies.\n\nAbout Breast Cancer and HER2/neu Positivity\n\nOne in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.\n\nAbout Greenwich LifeSciences, Inc.\n\nGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no ...